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Abstract. Children with cancer are particularly vulnerable to malnutrition, which can affect 
their tolerance of chemotherapy and outcome. In Nicaragua approximately two-thirds of 
children diagnosed with cancer present with under-nutrition. A nutritional program for children 
with cancer has been developed at “La Mascota” Hospital. Results of this oral nutritional 
intervention including difficulties, benefits, and relevance for children treated for cancer in low- 
and middle-income countries are here reported and discussed. 
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Introduction. The pediatric population diagnosed 
with cancer is at high risk of malnutrition for 
cancer and treatment related effects. Children with 
cancer tend to become malnourished during 
treatment because of multiple reasons. Pain, 
anorexia, hormonal and inflammatory 
components, low physical activity, taste aversions 
and chronic medications are all factors which lead 
to decreased oral calories intake and can 
contribute to malnutrition.1,2 Malnutrition can 
affect the tolerance of both chemotherapy and 
radiotherapy, may increase the risk of 
comorbidities and influence overall survival.3 
Approximately 80% of children and 
adolescents who are diagnosed with cancer live in 
low- and middle-income countries (LMICs), 
where access to quality care and chances of cure 
are limited. In LMICs, malnutrition represents one 
of the major obstacles to effective pediatric care, 
together with late diagnosis, abandonment of 
therapy, suboptimal supportive care, and 
inefficient health-care delivery systems.4 
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In LMICs it is estimated that the prevalence of 
malnutrition averages 50% in children with 
cancer.5 In Nicaragua, the prevalence of 
malnutrition in children under 5 years of age 
according to UNICEF is 30%, with 23% of 
children presenting severe malnutrition and 7% 
moderate malnutrition.6 A study performed in the 
hemato-oncology centers of the AHOPCA 
(Asociación de Hemato-Oncología Pediátrica 
Centro-Americana)7 countries, between 2004 and 
2007, showed that nutritional status of children 
with cancer at diagnosis was normal in 37% of 
patients, moderately depleted in 18% and severely 
depleted in 45%.8 In Nicaragua at the Children’s 
Hospital Manuel de Jesus Rivera “La Mascota” 
(HIMJR), 67% of patients were classified as 
malnourished at diagnosis, including 47.9% with 
severe malnutrition.9 
On the basis of these evidences, a nutritional 
program for children diagnosed with cancer who 
were inadequately nourished was developed at 
HIMJR, in collaboration with the Pediatric 
Hemato-Oncology Center of Monza (Milano-
Bicocca University), in the context of the Monza 
International School of Pediatric 
Hematology/Oncology (MISPHO) initiative.10 
HIMJR is the only hospital of Nicaragua where 
children with cancer can be treated; approximately 
250 children with cancer per year are referred 
from the whole country.  
The nutritional program started in February 
2016 with the objectives to reduce the adverse 
effect of malnutrition on treatment related 
morbidity and improve clinical outcome. 
The aim of this study is to assess the role of 
oral/enteral supplementation in children treated for 
oncological diseases in the context of LMICs, 
where this intervention still needs to be properly 
investigated. 
 
Material and Methods. Patients with cancer, 
aged one month to 17 years, diagnosed between 
February 2016 and March 2017 at the HIMJR 
were screened for nutritional status by a qualified 
nutritionist at diagnosis. The nutritional status 
assessment was based on weight, height or length 
and the anthropometric measures of mid upper 
arm circumference (MUAC) and triceps skin fold 
thickness (TSFT), as already reported.8 
TSFT and MUAC percentiles were estimated 
for age and gender using the LMS procedure 
according to the CDC and WHO growth charts.11 
Patients were considered adequately nourished 
(AN) if both TSFT and MUAC were >10th 
percentile, severely depleted (SD) if TSFT or 
MUAC <5th percentile, and moderately depleted 
(MD) in all other cases.  
Eligible for the study, after obtaining written 
informed consent from parents or legal guardians, 
were: 1) patients inadequately nourished at 
diagnosis, 2) patients with borderline nutritional 
status at diagnosis undergoing intensive 
chemotherapy, considered at high risk of 
developing under-nutrition by the nutritionist and 
treating physician, and 3) patients developing 
under-nutrition during the treatment. Children with 
advanced disease at diagnosis and eligible only for 
palliative care were excluded.  
Patients entered in the study were given oral 
polymeric hyper-caloric formulas containing a 
balanced mixture of proteins, fats, and 
carbohydrates according to the indication by age 
for patients up to 10 years or older (up to 17 
years). Parents were instructed to reconstitute 
formulas with water and to administer them to 
their children at home after discharge from the 
hospital. The adherence to the nutritional 
treatment was ascertained by the nutritionist from 
parents’ interviews.  
Only when oral feeding was not considered 
possible or safe, formulas were administered 
through enteral feeding. Nutritionists and treating 
physicians decided the schedule of nutritional 
reassessments on the basis of the clinical 
conditions and the treatment plan for each patient.  
Gender, date of birth, date of diagnosis, dates of 
nutritional assessment and type of cancer were 
recorded. The data were collected in the Pediatric-
Oncology-Network-Database (POND).12 
This study has made a comparison with a 
historical cohort of patients with comparable 
characteristics diagnosed from 2004 to 2007 at 
HIMJR,8 to evaluate the impact on event-free-
survival (EFS) of the addition of nutritional 
support. Their nutritional status has been here re-
classified according to the schema adopted in the 
current study. 
 
Statistical analysis. Patients’ characteristics were 
described using frequency, percentages, medians 
and interquartile range (IQR). The 1-year EFS was 
estimated in the overall cohort of 104 patients, and 
a comparison between the cohort in the study and 
the historical one was made using Kaplan Meier 
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survival curves and tested using Andersen pseudo-
values regression, adjusting for type of tumor and 
nutritional status at first evaluation. This test was 
adopted due to the extremely different follow-up 
duration of the two cohorts.  
P-values were considered statistically 
significant if lower than 0.05. Statistical analyses 
and figure were done with SAS v9.4, STATA and 
R. 
 
Results. A total of 259 children were diagnosed 
with cancer at HIMJR in the period of the study; 
of them, 104 entered the study and received 
nutritional supplementation. Nutritional formulas 
were given free of charge and were accepted by all 
families.  
Patients’ characteristics at the onset of disease 
are described in table 1. Forty-four were female 
(42.3%), and 60 were male (57.7%); 34 were 
affected by acute lymphoblastic leukemia (ALL), 
5 by acute myeloid leukemia, 13 by lymphomas 
and 52 by solid tumors, including brain tumors 
(n=20), retinoblastoma (n=3), bone and soft-tissue 
sarcoma (n=15), Wilms’ tumor (n=7) and others 
(n=7). Diseases were clustered in two groups -
leukemia/lymphomas and solid tumors- for further 
analyses.  
At the start of the nutritional support, the 
median age was 7.0 years (IQR: 3.4-11.5). Almost 
all patients (n=99) were exclusively orally 
supplemented; in only three patients the nutritional 
formula was administered via nasogastric tube and 
in two via gastrostomy. The nutritional 
supplementation was started within one month 
from diagnosis in 63 cases (60.6%), between 1 and 
2 months in 9 patients (8.6%) and later than 2 
months in 32 cases (30.8%). At first work-up 
(before supplementation) according to their 
anthropometric measurements patients were 
overall classified as follows: 65.4% severely 
depleted, 13.5% moderately depleted and 21.1% 
borderline/adequately nourished (considered at 
risk of developing under-nutrition during 
treatment) (Table 1). 
 
Table 1. Patients’ characteristics and nutritional status pre- and post-supplementation, by type of tumor. 
 Type of tumor Total N=104 
Patients characteristics Leuk./Lymph. N=52 Solid tumor N=52  
 N (%) N (%) N (%) 
Gender    
Female 19 (36.5) 25 (48.1) 44 (42.3) 
Male 33 (63.5) 27 (51.9) 60 (57.7) 
Age    
<1 1 (1.9) 0 (0.0) 1 (1.0) 
1-5 25 (48.1) 19 (36.5) 44 (42.3) 
6-9 10 (19.2) 11 (21.2) 21 (20.2) 
10-17  16 (30.8) 22 (42.3) 38 (36.5) 
Type of supplementation    
Oral 52 (100.0) 47 (90.4) 99 (95.2) 
Via nasogastric tube 0 (0.0) 3 (5.8) 3 (2.9 
Via gastrostomy 0 (0.0) 2 (3.8) 2 (1.9) 
Time from diagnosis to suppl. beginning    
< 1 month 36 (69.2) 27 (51.9) 63 (60.6) 
1-2 months 5 (9.6) 4 (7.7) 9 (8.6) 
> 2 months 11 (21.2) 21 (40.4) 32 (30.8) 
Nutritional status before supplementation     
     SD 31 (59.6) 37 (71.1) 68 (65.4) 
     MD 7 (13.5) 7 (13.5) 14 (13.5) 
     AN 14 (26.9) 8 (15.4) 22 (21.1) 
Nutritional status after supplementation*    
     SD 14 (36.8) 15 (57.7) 29 (45.3) 
     MD 6 (15.8) 6 (23.1) 12 (18.8) 
     AN 18 (47.4) 5 (19.22) 23 (35.9) 
*Data available in 64 patients. SD=severely depleted, MD=moderately depleted, AN=adequately nourished. 
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Table 2. Distribution of patients by nutritional status pre- and post-nutritional intervention, by type of tumor. 
Nutritional status 
before supplementation  
Nutritional status after supplementation  
SD MD AN Total 
N (%) N (%) N (%) N (%) 
Leuk./Lymph.     
SD 12 (50.0) 3 (12.5) 9 (37.5) 24 (63.2) 
MD 1 (33.3) 0 (0.0) 2 (67.7) 3 (7.9) 
AN 1 (9.1) 3 (27.3) 7 (63.6) 11 (28.9) 
Total 14 (36.8) 6 (15.8) 18 (47.4) 38 
Solid tumor     
SD 11 (57.8) 4 (21.1) 4 (21.1) 19 (73.1) 
MD 2 (66.7) 1 (33.3) 0 (0.0) 3 (11.5) 
AN 2 (50.0) 1 (25.0)   1 (25.0) 4 (15.4) 
Total       15 (57.7) 6 (23.1) 5 (19.2) 26 
SD=severely depleted, MD=moderately depleted, AN=adequately nourished. 
 
Seventeen patients died of progressive disease, 
and 23 did not have a nutritional follow-up. Thus, 
nutritional reassessment after supplementation was 
performed in 64 patients at a median time from the 
first assessment of 2.7 months (IQR 2.0-5.4); 29 of 
them were severely depleted (45.3%), 12 
moderately depleted (18.8%) and 23 adequately 
nourished (35.9%) (Table 1). Compared with the 
first evaluation there was a decrease in the 
percentage of severely depleted patients in both 
leukemia/lymphoma groups (from 63.2 to 36.8%) 
and the solid tumor group (from 73.1 to 57.7%). 
Furthermore, in leukemia/lymphoma group, we 
observed an increase in the percentage of 
adequately nourished patients from 28.9% to 
47.4% (Table 2)  
Overall, 55% of patients in leukemia/lymphoma 
group and 35% in the solid tumor group improved 
their condition or remained in an adequately 
nourished status. There was not a significant 
statistical difference between the proportions of 
patients improved by type of tumor (p-
value=0.104).  
The 1-year EFS of the overall cohort of patients 
recruited in this study was 70.1%, which compares 
favorably with that of a historical cohort of 
patients treated at HIMJR and not supplemented, 
who had a 1-year EFS of 60% (SE=2.8), p-
value=0.022 (Figure 1). 
Adjusting for the type of tumor and nutritional 
status at diagnosis the supplemented cohort 
seemed to have statistically significant 1-year EFS 
higher than the historical cohort (p-value=0.013, 
gain in EFS of about 13%, 95% CI=[2.9%-
24.0%]). 
Discussion. Malnutrition remains a critical health 
issue for pediatric oncology in LMICs, where the 
nutritional status of children with cancer has an 
important effect on the outcome, being associated 
with the risk of abandonment and low tolerance of 
therapy.8,9,13 Thus, children with oncological 
diseases should be regularly assessed for 
nutritional status and supported, as recommended 
by the SIOP PODC (Nutrition Working Group of 
the Society of Pediatric Oncology), that presented 
a framework for establishing and monitoring 
nutritional care, based on the infrastructure of 
institutions in LMICs.14 
A recent study performed in Guatemala in 
childhood ALL showed that establishing an 
appropriate nutritional program may overcome the 
adverse prognostic impact of malnutrition.15 Data 
on effects of oral/enteral nutritional support 
programs in pediatric cancer patients are, however, 
quite limited.16 Thus, there is still a need for 
further investigations to assess feasibility, costs 
and efficacy of nutritional interventions in children 
with cancer treated in LIMICs. 
Our experience demonstrates that oral 
supplementation with polymeric formulas has a 
favorable impact on the nutritional status in a 
relevant number of cases. Overall, in this study 
after the supplementation, 55% of patients in 
leukemia/lymphoma group and 35% in the solid 
tumor group improved their condition or remained 
in an adequately nourished status despite the 
toxicity of treatment. This intervention also 
appears to have contributed to improving the 1- 
year EFS as also reported in the Guatemala 
experience.15 
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Figure 1. Event free survival by cohort: supplemented vs. historical one 
 
The 1-year EFS comparison p-value between the supplemented and the historical cohort performed by the Andersen pseudo-values 
regression was 0.022.  
 
However, since a significant fraction of patients 
with severe malnutrition (23/43) did not improve 
their nutritional status, it may be inferred that a 
more intensive nutritional support with enteral 
feeding could have been more beneficial for these 
patients. In this study enteral-tube-feeding (ETF) 
was administered only in very few cases (5/104), 
due to fear of complications, particularly in 
patients with neutropenia, thrombocytopenia, and 
mucositis. These reasons may have played a role 
in inducing reluctance in both physicians and 
families to use ETF. The use of ETF may however 
be feasible also in these circumstances as 
suggested by a study published in 2001, which 
showed that tube feeding was safe and cost-
effective in children treated with intensive 
chemotherapy.17 Data in this field remain however 
extremely limited.18 The risk-benefit of the use of 
ETF should thus be carefully investigated, in order 
to define the most appropriate strategies of 
nutritional support in these patients, particularly in 
LMICs where the need of enteral nutrition but also 
the risk of complications may be higher compared 
to high-income countries. 
Another aspect of interest regards the use of 
commercial formulas. In our experience, these 
formulas, which are expensive and not easily 
available in LMICs, were often not well accepted 
by the patients and their parents, who would have 
instead favored homemade preparations. It should 
thus be considered the appropriateness of 
homemade oral supplements as a viable 
alternative, as described by a study conducted in 
Brazil.19 
Although the weaknesses related to the small 
number of patients, the shortage of personnel, the 
lack of standardization between first and second 
nutritional evaluation and the heterogeneity of 
disease population, this study in our opinion 
provides important information. Our experience 
indicates that oral nutritional support in children 
treated for cancer in LMICs may be helpful to 
improve outcome and that homemade formulas 
should be considered according to the local 
contexts. Large prospective studies should be 
conducted to establish the best cost-effective 
methodologies in LMICs and the role of enteral 
nutrition in the patients not responding to oral 
supplementation.  
Malnutrition in children with cancer should not 
be tolerated as an inevitable process,3 also and 
above all in LMICs, where nutritional 
interventions with the aim to prevent or reverse 
malnutrition should be part of routine supportive 
care in the treatment plan for childhood cancer. 
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